TY - JOUR
T1 - Raman spectroscopy for in-line and off-line quantification of poorly soluble drugs in strip films
AU - Zhang, Jun
AU - Ying, Ye
AU - Pielecha-Safira, Barbara
AU - Bilgili, Ecevit
AU - Ramachandran, Rohit
AU - Romañach, Rodolfo
AU - Davé, Rajesh N.
AU - Iqbal, Zafar
N1 - Publisher Copyright:
© 2014 Elsevier B.V. All rights reserved.
PY - 2014/11/20
Y1 - 2014/11/20
N2 - Raman spectroscopy was used as a process analytical technology (PAT) tool for in-line measurement of active pharmaceutical ingredient (API) content during continuous manufacturing of strip films containing nanoparticles of poorly water-soluble APIs. Fenofibrate and naproxen were used as model APIs, whose concentrations ranged from 3% to 26% (w/w) in the model calibration. For both in-line and off-line measurements, calibration models employed partial least square (PLS) analysis, yielding correlation coefficients (R2) greater than 0.9946 and root mean squared error of calibration (RMSEC) of about 0.44%, indicating the validity and accuracy of the calibration. The robustness of Raman spectroscopy as a PAT tool was established by considering three processing parameters after substrate interference correction: sensing location, substrate speed and film thickness. Calibration models for each API were validated using a separate batch of strip films by predicting the API concentrations to within ±1.3%. Principal component analysis (PCA) was used to explain the interactions between processing variables and calibration models, which suggest that besides API concentration, film thickness could also be monitored using Raman spectroscopy. The results demonstrate the potential of Raman spectroscopy as an effective PAT tool for novel strip film manufacturing process, facilitating detection of drug form and concentration in real-time.
AB - Raman spectroscopy was used as a process analytical technology (PAT) tool for in-line measurement of active pharmaceutical ingredient (API) content during continuous manufacturing of strip films containing nanoparticles of poorly water-soluble APIs. Fenofibrate and naproxen were used as model APIs, whose concentrations ranged from 3% to 26% (w/w) in the model calibration. For both in-line and off-line measurements, calibration models employed partial least square (PLS) analysis, yielding correlation coefficients (R2) greater than 0.9946 and root mean squared error of calibration (RMSEC) of about 0.44%, indicating the validity and accuracy of the calibration. The robustness of Raman spectroscopy as a PAT tool was established by considering three processing parameters after substrate interference correction: sensing location, substrate speed and film thickness. Calibration models for each API were validated using a separate batch of strip films by predicting the API concentrations to within ±1.3%. Principal component analysis (PCA) was used to explain the interactions between processing variables and calibration models, which suggest that besides API concentration, film thickness could also be monitored using Raman spectroscopy. The results demonstrate the potential of Raman spectroscopy as an effective PAT tool for novel strip film manufacturing process, facilitating detection of drug form and concentration in real-time.
KW - Calibration model
KW - In-line drug concentration monitoring
KW - Principal component analysis
KW - Raman spectroscopy
KW - Strip films
UR - http://www.scopus.com/inward/record.url?scp=84907221011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907221011&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2014.08.051
DO - 10.1016/j.ijpharm.2014.08.051
M3 - Article
C2 - 25173638
AN - SCOPUS:84907221011
SN - 0378-5173
VL - 475
SP - 428
EP - 437
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 1
ER -